Trial · NCT02289898

Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma

NCT02289898, Phase 2, Completed, OncoMed Pharmaceuticals, Inc.; results first posted 2018-08-08

3 sourcestrials-2026-11-12-0.4.0

Cite this record

ConductScience Library. Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma. Trials, record NCT02289898. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02289898

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma
NCT number: NCT02289898
Status: Completed
Phases: Phase 2
Enrollment: 207 participants, actual
Lead sponsor: OncoMed Pharmaceuticals, Inc.
Conditions: Pancreatic Cancer
Interventions: Demcizumab, Abraxane®, gemcitabine, Placebo
First posted: 2014-11-13
Last updated: 2020-09-28
Results first posted: 2018-08-08

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Hazard of Progression in the Placebo/Placebo Arm and the Pooled Demcizumab Arms	Investigator-assessed progression-free survival time through duration of the study (2 years, 23 days).	Investigator assessed Kaplan-Meier estimates of progression-free survival for placebo/placebo arm and pooled demcizumab arm.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Hazard of Progression in the Placebo/Placebo Arm and the Pooled Demcizumab Arms	Investigator-assessed progression-free survival time through duration of the study (2 years, 23 days).	Placebo/placebo arm and pooled demcizumab arms (ITT population).	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group8

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
Hazard of Progression in the Placebo/Placebo Arm and the Pooled Demcizumab Arms	Placebo/Placebo Arm	Progressed (event)	38	Participants
Hazard of Progression in the Placebo/Placebo Arm and the Pooled Demcizumab Arms	Demcizumab/Placebo and Demcizumab/Demcizumab	Progressed (event)	70	Participants
Hazard of Progression in the Placebo/Placebo Arm and the Pooled Demcizumab Arms	Placebo/Placebo Arm	Died (event)	5	Participants
Hazard of Progression in the Placebo/Placebo Arm and the Pooled Demcizumab Arms	Demcizumab/Placebo and Demcizumab/Demcizumab	Died (event)	12	Participants
Hazard of Progression in the Placebo/Placebo Arm and the Pooled Demcizumab Arms	Placebo/Placebo Arm	Censored, follow-up ended	3	Participants
Hazard of Progression in the Placebo/Placebo Arm and the Pooled Demcizumab Arms	Demcizumab/Placebo and Demcizumab/Demcizumab	Censored, follow-up ended	7	Participants
Hazard of Progression in the Placebo/Placebo Arm and the Pooled Demcizumab Arms	Placebo/Placebo Arm	Censored, follow-up ongoing	22	Participants
Hazard of Progression in the Placebo/Placebo Arm and the Pooled Demcizumab Arms	Demcizumab/Placebo and Demcizumab/Demcizumab	Censored, follow-up ongoing	47	Participants

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo/Placebo Arm	68
Overall Study	STARTED	Demcizumab/Placebo Arm	71
Overall Study	STARTED	Demcizumab/Demcizumab Arm	65
Overall Study	COMPLETED	Placebo/Placebo Arm	16
Overall Study	COMPLETED	Demcizumab/Placebo Arm	18
Overall Study	COMPLETED	Demcizumab/Demcizumab Arm	9
Overall Study	NOT COMPLETED	Placebo/Placebo Arm	52
Overall Study	NOT COMPLETED	Demcizumab/Placebo Arm	53
Overall Study	NOT COMPLETED	Demcizumab/Demcizumab Arm	56

Source ClinicalTrials.gov

Adverse events618

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Hypertension	Vascular disorders	Placebo/Placebo Arm	10	68	10
other	Hypertension	Vascular disorders	Demcizumab/Placebo Arm	17	71	17
other	Hypertension	Vascular disorders	Demcizumab/Demcizumab Arm	21	65	21
other	Hypotension	Vascular disorders	Placebo/Placebo Arm	11	68	11
other	Hypotension	Vascular disorders	Demcizumab/Placebo Arm	6	71	6
other	Hypotension	Vascular disorders	Demcizumab/Demcizumab Arm	5	65	5
other	Deep vein thrombosis	Vascular disorders	Placebo/Placebo Arm	7	68	7
other	Deep vein thrombosis	Vascular disorders	Demcizumab/Placebo Arm	4	71	4
other	Deep vein thrombosis	Vascular disorders	Demcizumab/Demcizumab Arm	9	65	9
other	Fatigue	General disorders	Placebo/Placebo Arm	34	68	34

1 to 10 of 618Source ClinicalTrials.gov

See all 618 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Placebo/Placebo Arm	5	68
Total, all-cause mortality	Demcizumab/Placebo Arm	12	71
Total, all-cause mortality	Demcizumab/Demcizumab Arm	3	65
Total, other adverse events	Placebo/Placebo Arm	68	68
Total, other adverse events	Demcizumab/Placebo Arm	71	71
Total, other adverse events	Demcizumab/Demcizumab Arm	65	65
Total, serious adverse events	Placebo/Placebo Arm	40	68
Total, serious adverse events	Demcizumab/Placebo Arm	49	71
Total, serious adverse events	Demcizumab/Demcizumab Arm	34	65

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Source

Release: trials-2026-11-12-0.4.0
Release manifest SHA-256: 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
Registry capture: 2026-11-12
Results copy, AACT: 2026-03-23
NIH clinical studies file: 2026-11-13

Source ClinicalTrials.gov

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNone stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02289898

GET https://conductscience.org/api/trials/v1/NCT02289898/events?page=2

API reference For AI assistants